Maternal exposure to AhR agonists has been proposed as a risk factor for breast cancer in the offspring through epigenetic inhibition of the tumor suppressor BRCA-1 (Breast cancer 1), whereas dietary AhR antagonists may exert protective effects against such disease (Papoutsis et al., 2015). The gene discussed is BRCA1; the disease is breast carcinoma.